Zoledronic Acid Market size is forecast to reach $2.19 billion by 2025, growing at a CAGR of 5.27% during the forecast period 2020-2025. Increased use of zoledronic acid with cancer chemotherapy to treat bone problems and rising bone related problems such as bone fractures, lower bone density and osteoporosis are the major factors driving the growth of the market. Decreased bone strength in the geriatric population and increased osteoporosis prevalence in postmenopausal women is set to further enhance the overall market demand of zoledronic acid during the forecast period 2020-2025.
- North America dominated the Zoledronic Acid Market in 2019 owing to its increasing usage in the treatment of hypercalcemia, osteoporosis and paget disease. The Zoledronic Acid Market scope for different regions will be provided in the final report.
- Increase in osteoporosis in postmenopausal woman is likely to aid in the market growth of Zoledronic acid.
- Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Zoledronic Acid Market report.
- Stringent government regulations and adverse effect of zolendronic acid is poised to create hurdles for the Zoledronic Acid Market.
Product Type- Segment Analysis
Zolendronic acid is used to prevent or treat osteoporosis in which bones become thin & weak and break easily. Zoledronic acid comes as a solution (liquid) to inject into a vein over at least 15 minutes. Zoledronic acid injection is used to treat high blood levels of calcium caused by cancer and is usually given as a single dose. A second dose is be given at least 7 days after the first dose if blood calcium does not drop to normal levels or does not remain at normal levels and it is also used to treat high blood calcium levels (hypercalcemia) that can occur with cancer. Zoledronic acid belongs to a class of drugs known as bisphosphonates. It lowers high blood calcium levels by reducing the amount of calcium released from the bones into the blood. It also works by slowing the breakdown of bones by cancer to prevent bone fractures. Also, Zolendronic acid is a white crystalline powder which is highly soluble in sodium hydroxide solution, sparingly soluble in water and practically insoluble in organic solvents. . Zometa is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors in conjunction with standard antineoplastic therapy. Injection is estimatedbe the highest growing segment of the zoledronic acid market in the forecast period 2020-2025.
Application – Segment Analysis
Zoledronic acid is used in the treatment of Metastatic Bone Cancers. Bone metastases are common in patients with advanced lung cancer and can have devastating consequences. Osteoporosis held the major share in Zoledronic Acid market in 2019 and is estimated to grow at a CAGR of 4.73% during the forecast period 2020-2025. Zoledronic acid is given once a year as an intravenous (IV) infusion to treat osteoporosis. It is also given every two years as an IV infusion to prevent osteoporosis. Zoledronic acid increases bone density and reduces the incidence of the spine and non-spine fractures, including hip fractures. Preventing or delaying bone metastases is set to improve outcomes. Bisphosphonates are inhibitors of osteoclast mediated bone resorption. The current indications for bisphosphonates include the treatment of metabolic disorders of bone metabolism. Zoledronic acid is a nitrogen-containing, third-generation bisphosphonate that has been approved for the treatment of postmenopausal osteoporosis as an annual intravenous infusion. Osteoporosis is estimated to be the fastest growing segment of Zoledronic acid market during the forecast period 2020-2025.
Geography – Segment Analysis
North America dominated the zoledronic acid market in 2019 with a share of more than 38.9%, followed by Europe owing to the increase in the prevalence of cancer and the changing sedentary lifestyle. An increase in the prevalence of osteoporosis in postmenopausal women and the increase in bone-related problems among the geriatric population is increasing the growth of the zoledronic acid market in this region.
However, Europe is estimated to grow at a higher CAGR during the forecast period 2020-2025 owing to the rising demand of zoledronic acid for the usage with cancer chemotherapy to treat bone problems that occur with multiple myeloma and other types of cancer.
Drivers – Zoledronic Acid Market
- Increase in obesity cases and bone related problems
Increase in obesity cases and bone related problems increased the growth of the zoledronic acid market. Zoledronic acid is the current standard of care for treating bone metastases from hormone refractory prostate cancer, advanced breast cancer, stage III multiple myeloma and advanced renal cancer. Zoledronic acid (Zometa) is the most recent addition to the clinically available bisphosphonates and has been increasingly used in children with primary and secondary osteoporosis owing to its convenience of shorter infusion time and thus increasing the growth of the zoledronic acid market.
- Increase in osteoporosis in postmenopausal woman
An increase in osteoporosis in the postmenopausal woman is increasing the growth of the zoledronic acid market. Zoledronic acid is a bisphosphonate which is a group of medications that work slowing down the cells that break down bone. It is an intravenous, amino bisphosphonate with a high affinity for mineralized bone, which could increase patients’ compliance with bisphosphonate therapy and thus improve the clinical outcome. It is the most commonly prescribed medication for people with osteoporosis in a postmenopausal woman as it increases bone density and reduces the incidence of the spine and nonspine fractures. Zoledronic acid is given every two years as an infusion to prevent osteoporosis. Thus, increasing the growth of the zoledronic market during the forecast period 2020-2025.
Challenges – Zoledronic Acid Market
- Stringent government regulations and adverse effect of zolendronic acid
Some of the factors that can impede the growth of the zoledronic acid market are stringent government regulations and adverse effect of zolendronic acid.
Zoledronic Acid Industry Outlook
Product launches, mergers and acquisitions, joint ventures and R&D activities are key strategies adopted by players in the Zoledronic Acid Market. In 2019, Zoledronic Acid Market share is consolidated by the top ten players present in the market. Zoledronic acid top 10 companies are Cipla Ltd , Emcure Pharmaceutical , Hangzhou Longshine Bio-Tech , Lianyungang Runzhong Pharm , Mylan Pharms Inc , Natco Pharma Ltd , Scinopharm Taiwan, Ltd , Taj Pharmaceutical Ltd , Tecoland Corp and Teva Pharmaceutical Industry Ltd among others
- In January 2016, Emcure Pharmaceutical acquires canada’s International Pharmaceutical Generics Ltd.
- In August 2016, Teva Pharmaceutical Industry Ltd announces acquisition of Anda Inc.